Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
The World Health Organization (WHO) classification of central nervous system (CNS) tumors requires detection of isocitrate dehydrogenase (IDH) 1/2 gene mutations in patients with adult-type diffuse glioma (ADG) for better management. In clinical practice, the detection of IDH1 is mainly achieved by IDH1-r132-specific immunohistochemistry (IHC), which has a sensitivity of 80% and a specificity of 100%. However, in some cases, nonspecific background staining or regional heterogeneity of IDH1 protein expression may warrant confirmatory genetic analysis. IDH1/2 mutation detection requires reliable detection methods.